Portage Biotech (PRTG)
(Delayed Data from NSDQ)
$0.30 USD
+0.03 (10.70%)
Updated Apr 22, 2024 11:53 AM ET
After-Market: $0.28 -0.02 (-6.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Portage Biotech Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 17 | 16 | 12 | 6 |
Income After Depreciation & Amortization | 0 | -17 | -16 | -12 | -6 |
Non-Operating Income | NA | -106 | 1 | -2 | 1 |
Interest Expense | NA | 0 | 0 | 0 | 1 |
Pretax Income | NA | -123 | -15 | -15 | -5 |
Income Taxes | NA | -18 | 4 | 2 | 2 |
Minority Interest | NA | 0 | -2 | -1 | -2 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -105 | -19 | -17 | -7 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -105 | -17 | -16 | -5 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -17 | -16 | -12 | -6 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -17 | -16 | -12 | -6 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 16.12 | 13.06 | 11.73 | NA |
Diluted EPS Before Non-Recurring Items | NA | -6.49 | -1.29 | -1.35 | NA |
Diluted Net EPS (GAAP) | NA | -6.49 | -1.29 | -1.35 | -0.49 |
Fiscal Year end for Portage Biotech Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.04 | 5.95 | 5.01 | 4.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.04 | -5.95 | -5.01 | -4.08 |
Non-Operating Income | NA | -44.83 | -0.12 | -1.06 | 3.26 |
Interest Expense | NA | 0.01 | 0.01 | 0.00 | 0.00 |
Pretax Income | NA | -48.88 | -6.07 | -6.07 | -109.41 |
Income Taxes | NA | -9.50 | -0.91 | -0.15 | -14.95 |
Minority Interest | NA | -0.01 | -0.01 | -0.01 | -0.01 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -39.38 | -5.17 | -5.93 | -94.46 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -39.37 | -5.16 | -5.92 | -94.45 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 20.90 | 17.80 | 17.70 | 16.17 |
Diluted EPS Before Non-Recurring Items | NA | -0.18 | -0.29 | -0.33 | -5.84 |
Diluted Net EPS (GAAP) | NA | -1.88 | -0.29 | -0.33 | -5.86 |